Patents by Inventor Wayne C. Schairer

Wayne C. Schairer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11274096
    Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as simulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said simulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: March 15, 2022
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
  • Publication number: 20220024909
    Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as stimulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said stimulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.
    Type: Application
    Filed: October 8, 2021
    Publication date: January 27, 2022
    Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
  • Publication number: 20210284632
    Abstract: The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), Compound (IA) and Compound (IB), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.
    Type: Application
    Filed: July 6, 2017
    Publication date: September 16, 2021
    Inventors: Song Xue, Vishnu Vardhan Reddy Karnati, Robert C. Livingston, Timothy Claude Barden, Wayne C. Schairer
  • Publication number: 20210053962
    Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as simulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said simulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.
    Type: Application
    Filed: January 10, 2019
    Publication date: February 25, 2021
    Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
  • Publication number: 20140187795
    Abstract: The present invention relates to processes and intermediates for the preparation of compounds useful as CRTH2 antagonists. Compounds prepared by the processes of the invention are of Formula (AI), (All) and Compound (I).
    Type: Application
    Filed: June 17, 2011
    Publication date: July 3, 2014
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: James Jia, Regina Graul, Wayne C Schairer, Vishnu Karnati, Ray Forslund
  • Publication number: 20130178453
    Abstract: The present disclosure relates to compounds useful as agonists of the cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders, either alone or in combination therapy. The compounds of the invention have Formula (I).
    Type: Application
    Filed: February 9, 2011
    Publication date: July 11, 2013
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Jason Rohde, Bo Peng, Takashi Nakai, Kevin Sprott, Ara Mermerían, Wayne C. Schairer, Galen John Carey
  • Patent number: 8426359
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: April 23, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, Robert B. Perni, Janos Pitlik, Wayne C. Schairer
  • Publication number: 20090291902
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Application
    Filed: November 5, 2008
    Publication date: November 26, 2009
    Inventors: Kevin M. Cottrell, Robert B. Perni, Janos Pitlik, Wayne C. Schairer
  • Publication number: 20090292135
    Abstract: The invention relates to chemical genera of organometal benzenephosphonates useful in cross-coupling organic synthesis, having general formula: where R is selected from boron, zinc, tin and silicon residues.
    Type: Application
    Filed: May 9, 2006
    Publication date: November 26, 2009
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Timothy C. Barden, Peter Lee, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley, JingJing Yang
  • Publication number: 20090131395
    Abstract: The invention relates to a chemical genus of 4-biphenyl-1-phenylazetidin-2-ones useful in the treatment of hypercholesterolemia and other disorders. The compounds have the general formula I: Pharmaceutical compositions and methods for treating cholesterol- and lipid-associated diseases are also disclosed.
    Type: Application
    Filed: May 5, 2006
    Publication date: May 21, 2009
    Applicant: MICROBIA, INC.
    Inventors: Stephen Antonelli, Regina Lundrigan, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley, Timothy C. Barden, JingJing Yang, Daniel P. Zimmer
  • Publication number: 20090099355
    Abstract: The present invention relates to processes for the production of 4-(biphenylyl)azetidin-2-one phosphonic acid derivatives of formula
    Type: Application
    Filed: May 25, 2006
    Publication date: April 16, 2009
    Applicant: MICROBIA, INC.
    Inventors: Stephen Antonelli, Timothy C. Barden, Peter Lee, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley
  • Publication number: 20080287663
    Abstract: The present invention relates to processes for the production of 4-biphenylylazetidin-2-one derivatives of formula
    Type: Application
    Filed: May 8, 2006
    Publication date: November 20, 2008
    Applicant: MICROBIA, INC.
    Inventors: Peter Lee, Stephen Antonelli, Regina Lundrigan, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley
  • Publication number: 20080200669
    Abstract: The present invention relates to processes for the production of phenolic 4-biphenylylazetidin-2-one derivatives of formula
    Type: Application
    Filed: May 11, 2006
    Publication date: August 21, 2008
    Applicant: Microbia, Inc.
    Inventors: Timothy C. Barden, Peter Lee, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley
  • Publication number: 20080167255
    Abstract: 4-Biarylyl-1-phenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of the general formula in which represents an aryl or heteroaryl residue; Ar represents an aryl residue; U is a two to six atom chain; and the R's represent substituents.
    Type: Application
    Filed: December 11, 2007
    Publication date: July 10, 2008
    Applicant: MICROBIA, INC.
    Inventors: Eduardo J. Martinez, John J. Talley, Stephen Antonelli, Timothy C. Barden, Regina Lundrigan-Soucy, Wayne C. Schairer, Jing-Jing Yang, Daniel P. Zimmer, Brian Cali, Mark G. Currie, Peter S. Yorgey
  • Patent number: 7320972
    Abstract: 4-Biarylyl-1-phenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of the general formula in which represents an aryl or heteroaryl residue; Ar represents an aryl residue; U is a two to six atom chain; and the R's represent substituents.
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: January 22, 2008
    Assignee: Microbia, Inc.
    Inventors: Eduardo Martinez, John J. Talley, Stephen Antonelli, Timothy C. Barden, Regina Lundrigan-Soucy, Wayne C. Schairer, Jing-Jing Yang, Daniel P. Zimmer, Brian Cali, Mark G. Currie, Peter S. Yorgey